RNXT צמיחת רווח נקי למניה השנה RenovoRx Corporation

סמלים רשמיים של חברת RenovoRx, Inc. (RNXT)

RenovoRx, Inc. (RNXT) retains top specialists through an innovative approach and generous stock options, as confirmed by the annual change in earnings per share shown on this chart using GURU.Markets data; the value 18.00 reflects the current metric volume. However, the complex certification process for combined drug delivery systems is delaying the payback period. Additionally, risks of delays in Phase 3 clinical trials and high expenditures are forcing the company to conduct secondary offerings.

צמיחת רווחים בשנה הנוכחית RenovoRx Corp (RNXT): לתקופה 04.07.2022 - 16.11.2026

פילוחים אנליטיים ודוחות נתונים של חברת RenovoRx (RNXT)

- שווי מניות ותחזית קונצנזוס למחירים:
הערכת שווי פונדמנטלית:RNXT RenovoRx Corporation
מוצרים מיוצרים של renovorx.com

RenovoRx, Inc. (RNXT) minimizes oncological risks by implementing precision drug delivery systems for pancreatic tumors. The effectiveness of these innovations is reflected in the year-over-year earnings per share (EPS) dynamics. This metric measures the rate of change in net income, signaling the business's operational resilience. Negative momentum in the annual EPS range warns of declining profitability. A drop in this indicator necessitates a revision of the investment strategy.